Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hanlim Pharm. Co., Ltd.
Age
19–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Healthy adult subjects aged ≥19 years at the time of screening
Subjects with no clinically significant congenital or chronic diseases based on screening, and no clinically significant findings on internal medicine examination (including, if necessary, electroencephalogram \[EEG\], electrocardiogram \[ECG\], chest examination, upper gastrointestinal endoscopy, or gastrointestinal radiography)
etc.
You may not be if
Subjects who have received medications known to markedly induce or inhibit drug-metabolizing enzymes (e.g., barbiturates) within 30 days prior to the screening visit
Subjects who have received any medications that may affect the outcome of the study within 10 days prior to the screening visit
etc.
Clareo Health | Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of HL1113-R1 and HL1113-R2 in Healthy Adult Volunteers
